A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...

But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that contribute to dementia risk, including obesity, type 2 diabetes ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

The biggest buzz around GLP-1 drugs these days has nothing to do with weight loss. And that might lead to some problems for ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

People with type 2 diabetes are more likely to develop Alzheimer’s disease and other types of dementia than the general public. This may be because the diseases have similar risk factors, like ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...